Jones Financial Companies’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.59M Buy
4,777
+1,817
+61% +$1.02M ﹤0.01% 1465
2026
Q1
$1.55M Buy
2,960
+2,207
+293% +$1.1M ﹤0.01% 1534
2025
Q4
$367K Buy
753
+142
+23% +$66.1K ﹤0.01% 1638
2025
Q3
$264K Buy
611
+82
+16% +$27.6K ﹤0.01% 1674
2025
Q2
$150K Sell
529
-49
-8% -$14.6K ﹤0.01% 1771
2025
Q1
$177K Buy
578
+282
+95% +$96.6K ﹤0.01% 1537
2024
Q4
$104K Buy
296
+258
+679% +$94.8K ﹤0.01% 1610
2024
Q3
$13.6K Buy
38
+25
+192% +$8.45K ﹤0.01% 2094
2024
Q2
$4.14K Buy
+13
New +$3.44K ﹤0.01% 1983
2013
Q4
– Sell
-27
Closed -$2K – 532
2013
Q3
$2K Sell
27
-811
-97% -$59.3K ﹤0.01% 658
2013
Q2
$55K Buy
+838
New +$54K ﹤0.01% 313

Other funds holding UTHR

Jones Financial Companies's UTHR Position: Q2 2026 in Review

Jones Financial Companies increased its United Therapeutics (UTHR) stake by 61% in Q2 2026, buying an estimated $1.02M and bringing the position to 4,777 shares worth $2.59M. The position accounts for ﹤0.01% of the portfolio, ranked #1465.

Jones Financial Companies first reported a position in UTHR in Q2 2013 and has held it in 11 quarters since. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Jones Financial Companies held 4,777 shares of United Therapeutics worth $2.59M as of Q2 2026.
  • Jones Financial Companies bought 1,817 United Therapeutics shares in Q2 2026, an estimated $1.02M.
  • United Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #1465 holding.
  • Jones Financial Companies first reported a position in United Therapeutics in Q2 2013 and has held it in 11 quarters since.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.